JPRN-UMIN000010293招募中未知
Parallel-group, multicenter, comparative study on the usefulness of nutrition therapy for patients with Crohn's disease Infliximab maintenance therapy - Parallel-group, multicenter, comparative study on the usefulness of nutrition therapy for patients with Crohn's disease Infliximab maintenance therapy
Graduate School of Medical Sciences, Kyushu University0 个研究点目标入组 80 人开始时间: 2013年3月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •This is true even if one of the following are excluded from the scope. (1)Patients with bowel obstruction (2)Patients with short bowel syndrome (3)Patients with advanced liver and kidney failure (4)Patients with abnormal glucose metabolism, such as severe diabetes (5)Patients with congenital disorders of amino acid metabolism (6)Patients with milk protein allergy (7)Patients with stoma (8) Other patients attending physician has determined inappropriate test
研究者
相似试验
未知
1 期
A phase 1 trial to determine the safety of OPC-108459 administered to subjects with atrial fibrillatioAtrial fibrillationJPRN-jRCT2080221673Otsuka Pharmaceutical Co., Ltd.70
进行中（未招募）
Unknown
A Prospective study Vildagliptin 100 mg Sustained Release Tablet once daily compared to Sitagliptin 100 mg Tablet in patients with Type 2 diabetes mellitusCTRI/2023/06/053737SV Private Limited
进行中（未招募）
1 期
A multi-center, parallel-group, comparative trial evaluating the efficacy, pharmacokinetics and safety of 4.0 mg.kg-1 sugammadex administered at 1-2 PTC in subjects with normal or severely impaired renal functioEUCTR2007-006935-29-FRV Organon70
进行中（未招募）
不适用
A multi-center, parallel-group, comparative trial evaluating the efficacy, pharmacokinetics and safety of 4.0 mg.kg-1 sugammadex administered at 1-2 PTC in subjects with normal or severely impaired renal functioot applicableEUCTR2007-006935-29-NLOrganon Nederland BV70
进行中（未招募）
1 期
A multi-center, parallel-group, comparative trial evaluating the efficacy, pharmacokinetics and safety of Org 25969 in subjects with normal or impaired renal function. - Springot ApplicableEUCTR2005-005050-47-GBV Organon30